CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.010
-0.040 (-3.81%)
Nov 4, 2024, 4:00 PM EST - Market closed
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.77, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 471.29% from the current stock price of 1.01.
Analyst Consensus: Buy
* Price targets were last updated on May 28, 2024.
Analyst Ratings
The average analyst rating for CTMX stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 27, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $2.25 → $3.5 | Hold → Buy | Upgrades | $2.25 → $3.5 | +246.53% | May 28, 2024 |
| BMO Capital | BMO Capital | Hold Maintains $3.25 → $3.59 | Hold | Maintains | $3.25 → $3.59 | +255.45% | May 9, 2024 |
Financial Forecast
Revenue This Year
103.20M
from 101.21M
Increased by 1.96%
Revenue Next Year
77.51M
from 103.20M
Decreased by -24.90%
EPS This Year
-0.32
from -0.01
EPS Next Year
-0.62
from -0.32
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 125.8M | 107.1M | 88.9M | ||
| Avg | 103.2M | 77.5M | 34.3M | ||
| Low | 80.4M | 30.4M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 24.2% | 3.8% | 14.7% | ||
| Avg | 2.0% | -24.9% | -55.7% | ||
| Low | -20.6% | -70.6% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.12 | -0.48 | -0.51 | ||
| Avg | -0.32 | -0.62 | -0.88 | ||
| Low | -0.52 | -1.08 | -1.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.